Published in Drug Week, May 29th, 2009
The corrected release reads: ST. JUDE MEDICAL ANNOUNCES FDA APPROVAL OF CURRENT PLUS ICD AND PROMOTE PLUS CRT-D DEVICES TO PROVIDE THERAPY FOR LIFE-THREATENING ARRHYTHMIAS AND HEART FAILURE St. Jude Medical, Inc. (NYSE:STJ) announced U.S. Food and Drug Administration (FDA) approval of the Promote® Plus cardiac resynchronization therapy defibrillator (CRT-D) and Current® Plus implantable cardioverter defibrillators (ICDs), designed with TailoredTherapy™ features that give physicians more options for customizing therapy for patients with potentially...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.